Literature DB >> 19187866

Immunology of hepatitis B and hepatitis C virus infections.

Andre Boonstra1, Andrea M Woltman, Harry L A Janssen.   

Abstract

Hepatitis B (HBV) and hepatitis C (HCV) viruses are the two major causes of chronic liver inflammation worldwide. Despite distinct virologic features, both viruses are preferentially hepatotropic, not directly cytopathic, and elicit liver diseases that share several aspects of their natural history. HBV and HCV infections also share some important features of the adaptive antiviral immune response. We describe the innate immune response in the early phase following infection, and how these early events may influence the development of the adaptive immune response in these two important viral infections. The mechanisms by which high levels of viral antigens, liver immunological features, the presence of regulatory T cells and impaired dendritic cell functions may maintain the HBV- and HCV-specific immunological failure, characteristic of chronic hepatitis B and C patients, are also evaluated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19187866     DOI: 10.1016/j.bpg.2008.11.015

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  18 in total

1.  The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases.

Authors:  João-Bruno Soares; Pedro Pimentel-Nunes; Roberto Roncon-Albuquerque; Adelino Leite-Moreira
Journal:  Hepatol Int       Date:  2010-10-21       Impact factor: 6.047

2.  Coffee, alcohol and other beverages in relation to cirrhosis mortality: the Singapore Chinese Health Study.

Authors:  George Boon-Bee Goh; Wan-Cheng Chow; Renwei Wang; Jian-Min Yuan; Woon-Puay Koh
Journal:  Hepatology       Date:  2014-06-24       Impact factor: 17.425

3.  Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice.

Authors:  Xianzheng Wang; Aihua Dong; Jingjing Xiao; Xingjun Zhou; Haili Mi; Hanqian Xu; Jiming Zhang; Bin Wang
Journal:  Cell Mol Immunol       Date:  2015-07-13       Impact factor: 11.530

4.  Molecular mechanisms of HBeAg in persistent HBV infection.

Authors:  Li-Min Chen; Xue-Gong Fan; Jing Ma; Bo He; Yong-Fang Jiang
Journal:  Hepatol Int       Date:  2016-05-18       Impact factor: 6.047

5.  Genetic association between CD44 polymorphisms and chronic hepatitis B virus infection in a Chinese Han population.

Authors:  Fan Li; Qing Shao; Dong Ji; Bing Li; Guofeng Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

6.  DNA Vectors Generating Engineered Exosomes Potential CTL Vaccine Candidates Against AIDS, Hepatitis B, and Tumors.

Authors:  Flavia Ferrantelli; Francesco Manfredi; Chiara Chiozzini; Simona Anticoli; Eleonora Olivetta; Claudia Arenaccio; Maurizio Federico
Journal:  Mol Biotechnol       Date:  2018-11       Impact factor: 2.695

7.  Negative regulation of hepatitis C virus specific immunity is highly heterogeneous and modulated by pegylated interferon-alpha/ribavirin therapy.

Authors:  Mark A A Claassen; Robert J de Knegt; Duygu Turgut; Zwier M A Groothuismink; Harry L A Janssen; André Boonstra
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

8.  Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function.

Authors:  Andrea M Woltman; Marjoleine L Op den Brouw; Paula J Biesta; Cui C Shi; Harry L A Janssen
Journal:  PLoS One       Date:  2011-01-05       Impact factor: 3.240

9.  Evaluation of IL-28B polymorphisms and serum IP-10 in hepatitis C infected chimpanzees.

Authors:  Babs E Verstrepen; Natasja G de Groot; Zwier M A Groothuismink; Ernst J Verschoor; Rik A de Groen; Willy M Bogers; Harry L A Janssen; Petra Mooij; Ronald E Bontrop; Gerrit Koopman; Andre Boonstra
Journal:  PLoS One       Date:  2012-10-30       Impact factor: 3.240

Review 10.  Nanotoxicity overview: nano-threat to susceptible populations.

Authors:  Yang Li; Yi Zhang; Bing Yan
Journal:  Int J Mol Sci       Date:  2014-02-28       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.